FDA analysis in California

2023(Dowhal, supra, 32 Cal.4th at p. 926 .) Thus, an FDA requirement can preempt a Proposition 65 warning only “on a basis relevant to consumer health, and not because the [warning] would frustrate the FDA’s policy favoring national uniformity.” (Ibid.) The Attorney General claims that under Dowhal, Proposition 65 cannot be preempted in this case unless there is “a conflict, relevant to consumer health, between providing a Proposition 65 cancer warning for NDMA exposure . . . and the FDA’s regulation of the[] products under the FDCA.” He argues that the federal duty of sameness “serves the FDCA’s

2023(Dowhal, supra, 32 Cal.4th at p. 926 .) Our state Supreme Court rejected the argument that “any nonidentical state warning would constitute misbranding,” as that “would nullify the savings clause . . . , which plainly permits Proposition 65 warnings that differ from the FDA warnings.” (Id. at p. 934.) But here, a determination that the federal duty of sameness prevents the generic-drug defendants from unilaterally adding Proposition 65 warnings to their labeling would not nullify section 379r’s savings clause.

2015Relying on the United States Supreme Court decision in Geier v. American Honda Motor Co., supra, 529 U.S. 861 , our Supreme Court concluded in Dowhal that the savings clause “does not entirely exclude conflict preemption” (Dowhal, supra, 32 Cal.4th at p. 926 ), and accordingly, the FDA’s directive could invalidate a Proposition 65 label “on a basis relevant to consumer health,” although not to pursue a policy of “national uniform labeling.” {Ibid.) The Supreme Court deferred to the FDA’s balancing of competing risks, observing that this was “an unusual case.” (Id. at p. 934.) While in most cas

2015Relying on the United States Supreme Court decision in Geier v. American Honda Motor Co., supra, 529 U.S. 861 , our Supreme Court concluded in Dowhal that the savings clause “does not entirely exclude conflict preemption” (Dowhal, supra, 32 Cal.4th at p. 926 ), and accordingly, the FDA’s directive could invalidate a Proposition 65 label “on a basis relevant to consumer health,” although not to pursue a policy of “national uniform labeling.” (Ibid.) The Supreme Court deferred to the FDA’s balancing of competing risks, observing that this was “an unusual case.” (Id. at p. 934.) While in most cas

2014Permitting this claim to proceed would essentially allow a private litigant to attempt to enforce the FDCA.” (Houston, supra, 957 F.Supp.2d at p. 1178 , italics added; see Caplinger, supra, 921 F.Supp.2d at p. 1223 ; but see Alton v. Medtronic, Inc. (D.Or. 2013) 970 F.Supp.2d 1069, 1103-1104 [concluding negligence claim involving off-label promotion is not preempted].) We conclude that Coleman’s negligence claim is not preempted.

2014Permitting this claim to proceed would essentially allow a private litigant to attempt to enforce the FDCA.” (Houston, supra, 957 F.Supp.2d at p. 1178 , italics added; see Caplinger, supra, 921 F.Supp.2d at p. 1223 ; but see Alton v. Medtronic, Inc. (D.Or. 2013) 970 F.Supp.2d 1069, 1103-1104 [concluding negligence claim involving off-label promotion is not preempted].) We conclude that Coleman’s negligence claim is not preempted.

2008(See Riegel v. Medtronic, Inc. (2nd Cir.2006) 451 F.3d 104, 118 , cert, granted June 25, 2007, ___ U.S. ___, 127 S.Ct. 3000 , 168 L.Ed.2d 725 .) The manufacturer cannot make any changes that may affect the safety or effectiveness of the device without further FDA approval.

2008(See Riegel v. Medtronic, Inc. (2d Cir. 2006) 451 F.3d 104, 118 , cert. granted June 25, 2007, _ U.S. ___ [ 168 L.Ed.2d 725 , 127 S.Ct. 3000 ].) The manufacturer cannot make any changes that may affect the safety or effectiveness of the device without further FDA (Food and Drug Administration) approval.

2008Manufacturers must submit detailed information regarding the safety and efficacy of their devices, which the *719 FDA then reviews, spending an average of 1,200 hours on each submission." ( Medtronic, supra, 518 U.S. at p. 477 , 116 S.Ct. 2240 .) A product's labeling is also within the purview of the PMA process. (21 U.S.C. § 360e(d)(2)(A), (B), (D); Steele v. Collagen Corp. (1997) 54 Cal.App.4th 1474, 1488 , 63 Cal.Rptr.2d 879 ( Steele ) ["`"FDA retains rigid control over the entirety of the labeling and packaging of class III products"'"; "the product's sponsor must submit a proposed label t

2008Manufacturers must submit detailed information regarding the safety and efficacy of their devices, which the FDA then reviews, spending an average of 1,200 hours on each submission.” (Me dtronic, supra, 518 U.S. at p. 477 .) A product’s labeling is also within the purview of the PMA process. (21 U.S.C. § 360e(d)(2)(A), (B), (D); Steele v. Collagen Corp. (1997) 54 Cal.App.4th 1474, 1488 [ 63 Cal.Rptr.2d 879 ] (Steele) [“ ‘ “FDA retains rigid control over the entirety of the labeling and packaging of class III products” ’ “the product’s sponsor must submit a proposed label to the FDA for analysi

2008(See Riegel v. Medtronic, Inc. (2nd Cir.2006) 451 F.3d 104, 118 , cert, granted June 25, 2007, ___ U.S. ___, 127 S.Ct. 3000 , 168 L.Ed.2d 725 .) The manufacturer cannot make any changes that may affect the safety or effectiveness of the device without further FDA approval.

2008(See Riegel v. Medtronic, Inc. (2d Cir. 2006) 451 F.3d 104, 118 , cert. granted June 25, 2007, _ U.S. ___ [ 168 L.Ed.2d 725 , 127 S.Ct. 3000 ].) The manufacturer cannot make any changes that may affect the safety or effectiveness of the device without further FDA (Food and Drug Administration) approval.

2022“Hallmarks of background facts,” the court said, “are that they are generally accepted by experts in their field of expertise, and that they will usually be applicable to all similar cases.” (Id. at p. 836.) Testimony about such facts may concern “ ‘background information regarding [the expert’s] knowledge and expertise and premises generally accepted in his field.” (Id. at p. 835.) Thus, a physician may “ ‘relate generally accepted medical knowledge that will assist the jury’ ” without “ ‘personally replica[ting] all medical experiments dating back to the time of Galen.’ ” (Id. at p. 836.) An

2020(Buckman Co. v. Plaintiffs’ Legal Committee (2001) 531 U.S. 341, 352 (Buckman).) Section 337(a) provides that “all . . . proceedings for the enforcement, or to restrain violations, of [the MDA] shall be by and in the name of the United States.” This provision prohibits claims that “seek[] to enforce an exclusively federal requirement that is not grounded in traditional state tort law.” (Glennen, supra, 247 Cal.App.4th at p. 11 , italics added.) Thus, if an FDA requirement is “a critical element” of a plaintiff’s tort claim, the claim conflicts with the MDA’s enforcement scheme and is impliedly

2020(Buckman, at pp. 352-353.) Together, express preemption under section 360k(a) and implied preemption under section 337(a) and Buckman create a “‘“‘narrow gap’ through which a state-law claim must fit to [survive] preemption.”’” (Glennen, supra, 247 Cal.App.4th at p. 11 .) The claim must be based on “‘“conduct that violates the [MDA],”’” but the plaintiff cannot be “‘“suing because the conduct violates the [MDA].”’” (Id. at pp. 11-12, original italics.) Thus, “‘“to survive preemption, [a] claim[] ‘must be premised on conduct that both (1) violates the [MDA] and (2) would give rise to a recovery

1997The FDA may withdraw approval of the device permanently or suspend its approval temporarily at any time if it determines that the device has become unsafe or its labeling inadequate. (21 U.S.C. § 360e(e).)" ( Scott v. CIBA Vision Corp., supra, 38 Cal. App.4th at pp. 317-318.) While the design or labeling of a device may be changed to enhance the safety without prior approval from the FDA, the manufacturer must submit to the FDA a PMA supplement and obtain acknowledgment from the FDA of receipt of the supplement. ( 21 C.F.R. § 814.39 (1996).) The device is still subject to withdrawal from the m